14 Peptides Are Coming Back to Your Physician's Toolkit — Here’s What That Means for You

A landmark regulatory reversal is about to restore physician access to some of the most powerful tools in regenerative and anti-aging medicine.

If you’ve been a patient at The Evergreen Institute — or if you’ve been following the peptide therapy landscape over the past few years — you know it’s been a frustrating stretch. Peptides that many of our patients relied on for tissue repair, metabolic optimization, immune support, and healthy aging were abruptly restricted from compounding pharmacies in late 2023. Our clinical team was forced to work around an access problem that perhaps never should have existed in the first place.

That’s about to change.

What Just Happened

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on The Joe Rogan Experience (Episode #2461) that approximately 14 of the 19 peptides the FDA had placed on its Category 2 “do not compound” list would be moved back to Category 1 status. That reclassification means licensed compounding pharmacies across the United States will once again be legally permitted to prepare these peptides for patients — with a valid physician’s prescription.

“We created the gray market.” — RFK Jr., acknowledging that restricting physician access didn’t eliminate patient demand. It just pushed patients toward unregulated overseas suppliers.

Kennedy stated that the original Category 2 classifications were made without legitimate safety signals and that the reclassification would occur within weeks of the announcement. At The Evergreen Institute, we have been closely monitoring this development and are preparing to restore these therapies to our protocols as soon as official FDA guidance is published and compounding pharmacies confirm compliance.

Which Peptides Are Coming Back?

While the FDA has not yet published its final updated list, the peptides expected to return to Category 1 status include:

•       BPC-157 — gut lining repair, soft tissue healing, anti-inflammatory support

•       CJC-1295 — growth hormone-releasing hormone analogue for body composition and recovery

•       Thymosin Alpha-1 — immune system regulation and modulation

•       AOD-9604 — metabolic health and fat metabolism support

•       MOTS-c — mitochondrial health, metabolic optimization, and longevity signaling

•       GHK-Cu — copper peptide with anti-aging, wound healing, and collagen synthesis properties

•       Selank — anxiolytic and cognitive enhancement

•       Semax — neuroprotective and cognitive support

•       KPV — anti-inflammatory, gut and skin support

•       Epitalon — telomere support and pineal gland regulation

Several of these — including BPC-157, CJC-1295, and MOTS-c — are core to the protocols we use at Evergreen for our most advanced longevity and performance patients. Their return is genuinely significant.

What “Category 1” Actually Means

This is an important distinction, and we want to be clear about it. Moving from Category 2 to Category 1 means a peptide is eligible for compounding by licensed pharmacies under Section 503A or 503B — with a valid prescription from a licensed provider. It does not mean the peptide has received FDA drug approval. These remain prescription-only treatments, prepared to individualized patient specifications, under physician supervision.

Legal to compound ≠ FDA approved. These peptides are powerful tools. They deserve physician oversight, not gray-market sourcing. That’s exactly the model we’ve always operated under at The Evergreen Institute.

What Hasn’t Changed at Evergreen

Our standards. Our sourcing protocols. Our commitment to physician-led care.

Every peptide protocol at The Evergreen Institute is designed and overseen by a board-certified physician. We source exclusively from FDA-registered, U.S.-based compounding pharmacies that comply with USP 797 and USP 795 standards. We conduct a full clinical evaluation — health history, labs, medications, and treatment goals — before any therapy is prescribed. That didn’t change when these peptides were restricted, and it won’t change now that they’re coming back.

What the reclassification does change: we can now once again offer our patients legal, regulated, high-quality access to therapies that many of them spent the past two years trying to find through workarounds.

A Word of Caution About the Gray Market

During the restriction period, many patients turned to “research use only” peptide vendors — suppliers operating in a legal gray zone, selling compounds with no standardized pharmaceutical oversight. We understand why. But the quality variance was enormous, and the risks were real.

Now that physician-supervised, compounding pharmacy access is being restored, there is no good reason to take on the risk and uncertainty of gray-market sources. If you’ve been self-sourcing, this is the moment to transition back to a medically supervised protocol.

What Comes Next

We are actively monitoring the FDA’s official publication of the updated bulk drug substances list. Once that guidance is released and our pharmacy partners confirm Category 1 compliance, we will begin reintegrating these peptides into available treatment protocols.

If you are a current patient interested in adding peptide therapy to your plan — or if you’d like to discuss whether any of these returning peptides are appropriate for your specific health goals — we encourage you to schedule a consultation. Our telemedicine platform allows us to see patients across 18 states, so geography is rarely a barrier.

Your Biology Deserves Better Than a Workaround.

The peptides are coming back. Physician-supervised access is being restored. Now is the time to build a protocol that is not only effective — but legal, safe, and designed specifically for you.

►  Schedule Your Consultation at The Evergreen Institute  ◄

TheEvergreenInstitute.org  |  Telemedicine Available Across 18 States  |  Opelika, AL

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Peptide therapies require evaluation and prescription by a licensed physician. The FDA has not yet published its final updated list of Category 1 peptides as of this writing. All protocols at The Evergreen Institute are individualized and subject to clinical evaluation. Not all therapies are appropriate for all patients.